Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuphoria TherapeuticsNEUP -0.78%24 3-1 Month Momentum % is -33.33% as of Aug. 11, 2026. GuruFocus rates NEUP with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,385 Biotechnology companies, Neuphoria Therapeutics ranks worse than 84.62% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-11), Neuphoria Therapeutics's 3-1 Month Momentum % is -33.33%.
The industry rank for Neuphoria Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
NEUP's 3-1 Month Momentum % is ranked worse than 84.62% of 1385
companies
in the Biotechnology industry
Industry Median: -7.28
vs NEUP: -33.33
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Neuphoria Therapeutics 3-1 Month Momentum % Related Terms
NEUP vs DARE, CLRB, LGVN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Neuphoria Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuphoria Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Neuphoria Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuphoria Therapeutics (NEUP) has a 3-1 Month Momentum % of -33.33% as of Aug. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Neuphoria Therapeutics and its competitors. According to the industry distribution chart, Neuphoria Therapeutics ranks #1172 out of 1385 companies in the Biotechnology industry, placing it in the top 84.6%.
Is Neuphoria Therapeutics' 3-1 Month Momentum % too high?
Neuphoria Therapeutics' current 3-1 Month Momentum % is -33.33%. Based on the distribution chart, Neuphoria Therapeutics ranks #1172 out of 1385 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' 3-1 Month Momentum % compare to DARE and CLRB?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #1172 out of 1385 companies for 3-1 Month Momentum %. This places Neuphoria Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current 3-1 Month Momentum % is -33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current 3-1 Month Momentum % of -33.33%. The current 3-1 Month Momentum % is -33.33%. Neuphoria Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current 3-1 Month Momentum % is -33.33% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
24GF Score
Get the complete analysis for NEUP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUP has been successfully added to your 
